Esophageal adenocarcinoma is a malignant tumor originating from the glandular epithelium of the esophagus, and almost all cases are located at the distal esophagus/gastroesophageal junction (GEJ). Its incidence has dramatically increased in Western countries over the past 40 years and now accounts for 60-70% of esophageal carcinomas in the US/Europe. It develops from Barrett esophagus (intestinal metaplasia); the Barrett metaplasia → low-grade dysplasia → high-grade dysplasia → adenocarcinoma sequence is followed. Gastroesophageal reflux disease (GERD), obesity, and male sex are the main risk factors. Male-to-female ratio is 7-8:1. HER2 amplification is found in 20-30% of cases and is important for targeted therapy.
Age Range
45-80
Peak Age
65
Gender
Male predominant
Prevalence
Common
Esophageal adenocarcinoma follows a metaplasia-dysplasia-carcinoma sequence initiated by chronic gastroesophageal reflux exposing the distal esophageal mucosa to repeated acid and bile injury. Normal squamous epithelium transforms to intestinal-type columnar epithelium (Barrett metaplasia) — this transformation occurs through activation of intestinal transcription factors such as CDX2 and MUC2. This metaplastic epithelium containing goblet cells progresses through dysplasia and then invasive carcinoma via genetic alterations including p53 mutation, p16 loss, and DNA aneuploidy. The tumor spreads along the distal esophageal wall and can invade periesophageal fat and mediastinal structures. Because lymphatic drainage is dual (mediastinal and abdominal), it can metastasize to lymph nodes in both thorax and abdomen. Asymmetric thickening and enhancement at the GEJ on CT reflects this invasive process.
Asymmetric, heterogeneously enhancing wall thickening and soft tissue mass at the distal esophagus/GEJ level. Highly specific for adenocarcinoma combined with Barrett esophagus/GERD history. Unlike SCC, distal localization and Barrett association support the diagnosis.
Asymmetric or circumferential wall thickening (>5 mm, usually 10-30 mm) at the distal esophagus/GEJ level. The tumor shows heterogeneous enhancement. The mass may also involve the gastric cardia (Siewert classification). Luminal narrowing and proximal dilation are seen.
Report Sentence
Asymmetric wall thickening and heterogeneously enhancing soft tissue mass measuring approximately ___ cm at the distal esophagus/GEJ level; adenocarcinoma should be the primary consideration.
Enlarged lymph nodes at the celiac axis, gastrohepatic ligament, and periesophageal stations (short axis >10 mm). Due to dual lymphatic drainage pattern, both abdominal and mediastinal lymphadenopathies may be seen. Lymph nodes may show enhancement or central necrosis.
Report Sentence
Pathologically enlarged lymph nodes with short axis up to ___ mm at the celiac axis/periesophageal region; consistent with metastatic lymphadenopathy.
The liver is the most common distant metastasis site. Multiple hypodense lesions, low density compared to surrounding parenchyma on portal venous phase. May show rim enhancement. Peritoneal carcinomatosis and lung metastases may also be seen.
Report Sentence
Multiple hypodense lesions in the liver; in the context of known esophageal adenocarcinoma, consistent with hepatic metastases.
Prominent FDG uptake at the GEJ level (SUVmax typically 5-20). Critical for primary tumor, locoregional, and distant metastasis staging. May be false negative in mucinous subtypes (low cellularity). Used for treatment response assessment (after neoadjuvant CRT).
Report Sentence
Wall thickening at the GEJ level demonstrating prominent FDG uptake with SUVmax ___; consistent with primary esophageal adenocarcinoma.
The tumor shows high signal on DWI (diffusion restriction). Low ADC values on ADC map (high cellularity). In treatment response assessment, ADC increase (cell death) indicates favorable response. Supports T staging together with EUS.
Report Sentence
The mass at the GEJ level demonstrates diffusion restriction on DWI, consistent with a highly cellular malignant lesion.
Irregular stricture at the distal esophagus/GEJ. Mucosal destruction, ulceration, and nodular mucosal pattern are seen. Extension to the fundus may be visible. Proximal esophageal dilation is associated. In early lesions, irregular mucosal relief or small polypoid lesion.
Report Sentence
Irregular mucosal destruction and stricture at the distal esophagus/GEJ; consistent with adenocarcinoma.
Criteria
Tumor center 1-5 cm proximal to GEJ. True esophageal adenocarcinoma.
Distinct Features
Develops on Barrett background. Treated with transthoracic esophagectomy. Mediastinal LAP more common.
Criteria
Tumor center between 1 cm proximal and 2 cm distal to GEJ.
Distinct Features
Most common type. Surgical approach debated (esophagectomy vs gastrectomy). Both mediastinal and abdominal LAP.
Criteria
Tumor center 2-5 cm distal to GEJ. Gastric cardia carcinoma extending to GEJ.
Distinct Features
Total gastrectomy + distal esophagectomy. Predominantly abdominal LAP. Weak Barrett association.
Criteria
Extracellular mucin comprises >50% of tumor volume.
Distinct Features
Low density on CT (due to mucin). Low FDG uptake on PET-CT (low cellularity). Worse prognosis.
Distinguishing Feature
SCC prefers mid-esophagus, alcohol/tobacco related; adenocarcinoma at distal esophagus/GEJ, Barrett/GERD related
Distinguishing Feature
GIST is submucosal, smooth-bordered, exophytic mass; adenocarcinoma shows mucosal-origin asymmetric thickening and ulceration
Distinguishing Feature
Barrett esophagus is observed without wall thickening; adenocarcinoma shows marked wall thickening, mass, and enhancement
Distinguishing Feature
Benign stricture is smooth-bordered and symmetric; adenocarcinoma is irregular, asymmetric with mucosal destruction
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralHistopathological confirmation with endoscopic biopsy is mandatory. HER2 testing (immunohistochemistry + FISH) should be performed. Staging with CT + PET-CT + EUS. In early stage (T1a), endoscopic mucosal resection/endoscopic submucosal dissection may be curative. In locally advanced disease, neoadjuvant chemotherapy (FLOT regimen) or chemoradiotherapy (CROSS) + surgery is standard. Trastuzumab is added in HER2-positive cases. Immunotherapy (nivolumab/pembrolizumab) can be applied in PD-L1 positive cases.
Treatment of esophageal adenocarcinoma is stage-dependent. Barrett dysplasia can be treated with endoscopic ablation. Early stage disease undergoes endoscopic resection, locally advanced disease requires neoadjuvant chemoradiation + surgery (CROSS regimen). Trastuzumab may be added in HER2-positive cases.